|
Year
|
Title
|
Authors
|
Publication
|
|
2020
|
Comprehensive prognostication in critically ill pediatric hematopoietic cell transplant patients: Results from merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.
|
Zinter MS, Logan BR, Fretham C, Sapru A, Abraham A, Aljurf MD, Arnold SD, Artz A, Auletta JJ, Chhabra S, Copelan E, Duncan C, Gale RP, Guinan E, Hematti P, Keating AK, Marks DI, Olsson R, Savani BN, Ustun C, Williams KM, Pasquini MC, Dvorak CC
|
Biol Blood Marrow Transplant 26(2):333-342
|
|
2020
|
Incidence, risk factors, and outcomes of patients who develop mucosal barrier injury-laboratory confirmed bloodstream infections in the first 100 days after allogeneic hematopoietic stem cell transplant.
|
Dandoy CE, Kim S, Chen M, Ahn K-W, Ardura MI, Brown V, Chhabra S, Diaz MA, Dvorak C, Farhadfar N, Flagg A, Ganguly S, Hale GA, Hashmi SK, Hematti P, Martino R, Nishihori T, Nusrat R, Olsson RF, Rotz SJ, Sung AD, Perales M-A, Lindemans CA, Komanduri KV, Riches ML
|
JAMA Netw Open 3(1):e1918668
|
|
2020
|
Health care reimbursement, service utilization, and financial responsibility among Medicare beneficiaries with multiple myeloma receiving autologous hematopoietic cell transplantation in inpatient and outpatient settings.
|
Dunavin N, Mau L-W, Meyer CL, Divine C, Leppke S, D'Souza A, Denzen E, Saber W, Burns LJ, Ganguly S
|
Biol Blood Marrow Transplant
|
|
2020
|
Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?
|
Dreger P, Fenske TS, Montoto S, Pasquini MC, Sureda A, Hamadani M
|
Biol Blood Marrow Transplant
|
|
2020
|
Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501
|
Pidala J, Hamadani M, Dawson P, Martens M, Alousi A, Jagasia MH, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JL, Levine JE, Mielcarek M, Anasetti C, Antin J, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML
|
Blood 135(2):97-107
|
|
2020
|
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
|
Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL
|
Biol Blood Marrow Transplant 26(1):e7-e15
|
|
2020
|
Causal inference in randomized clinical trials.
|
Zheng C, Dai R, Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(1):4-8
|
|
2020
|
Statistical analyses of clinical trials in haematopoietic cell transplantation or why there is a strong correlation between people drowning after falling out of a fishing boat and marriage rate in Kentucky.
|
Gale RP, Zhang M-J
|
Bone Marrow Transplant 55(1):1-3
|
|
2020
|
Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: A retrospective cohort study.
|
Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, Horowitz M, Hsu K, Madrigal JA, Maiers MJ, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P
|
Lancet Haematol 7(1):e50-e60
|
